Breast Cancer Stem Cell-Associated Extracellular Vesicles: Bioengineering Advances in Source-Resolved Isolation, Mechanistic Validation, and Clinical Translation

Abstract

Breast cancer stem cells (BCSCs) drive therapeutic resistance, recurrence, and metastasis via self-renewal, phenotypic plasticity, and adaptive tolerance to treatment and microenvironmental stress. Extracellular vesicles (EVs) mediate bidirectional intercellular communication between stem-like tumor cells and tumor, stromal, immune and vascular compartments, but their translation is blocked by critical unaddressed gaps: BCSC rarity and heterogeneity, incomplete donor-cell validation, uncertain vesicle-source attribution, and nonstandardized assays. This review outlines a unifying bioengineering framework built around source-resolved analysis to integrate BCSC enrichment, EV characterization, functional validation and translational development and evaluate current platforms for BCSC isolation (including flow cytometry, magnetic enrichment, microfluidic sorting, affinity capture, and single-cell platforms), EV purification, biosensing, single-vesicle profiling, and multimarker detection, alongside organoid and tumor-on-chip models for dissecting EV-driven resistance and metastatic niche remodeling. BCSC-associated EV signatures complement circulating tumor cells and circulating tumor DNA for noninvasive monitoring of stemness dynamics, treatment adaptation, and recurrence risk, while engineered EVs offer a unique targeted delivery route to resistant tumor states. Real-world deployment will require direct head-to-head comparison with clinically established nanocarriers for efficacy, manufacturability, biodistribution and safety. The eventual clinical translation of this field hinges on validated BCSC identity, reliable EV source attribution, standardized detection protocols, causal mechanistic validation, and scalable manufacturing.